Sign in
Taking peopleNo phase

Checking a computer score that spots hidden cancer in people with blood clots

Tests the CLOVER score for finding hidden cancer in adults with venous thromboembolism.

Key facts

Who runs it
Infanta Leonor University Hospital
Where
Spain12 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients
Status
Recruiting
People taking part
500 people, planned
Started
1 Dec 2025
Expected to end
31 Dec 2028
Type of study
Observational
Record updated
30 December 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a recent blood clot in a vein (deep vein thrombosis and/or pulmonary embolism) that causes symptoms. It tests the CLOVER score, a tool that estimates the chance of a hidden cancer.

Age
18 years and older
Sex
All sexes
Disease stage
Acute venous thromboembolism that causes symptoms and is confirmed by tests (deep vein thrombosis and/or pulmonary embolism).

Main reasons for not taking part

  • Cancer was suspected during the first tests for the blood clot.
  • Taking part in another treatment study that may affect the results.
  • Not able or not willing to give informed consent.

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age ≥18 years
  • Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism)
  • Ability to provide written or electronic informed consent

Who cannot take part

  • Suspicion of cancer during the initial diagnostic evaluation for VTE
  • Participation in another interventional study that may interfere with outcomes
  • Inability or refusal to provide informed consent

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.

The group in the trial

  • Prospective VTE Cohort

    Adults with objectively confirmed symptomatic venous thromboembolism (deep vein thrombosis and/or pulmonary embolism) consecutively enrolled from December 2025 to December 2027 in participating hospitals. All participants will undergo routine clinical evaluation, laboratory testing, and cancer screening according to standard practice. The CLOVER score will be calculated at baseline using the web-based tool (CLOVER-Web).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
External Validation of a Predictive Model for Occult Cancer Risk in Patients With Venous Thromboembolism Developed Using Machine Learning
Plain-language title
Checking a computer score that spots hidden cancer in people with blood clotsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
30 December 2025